Using immune responses to treat Leukemia
Acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) are myeloid malignancies with a poor prognosis. Allogenic hematopoietic stem-cell transplantation (HSCT) is often used to treat these conditions, to induce a graft versus leukemia immune response. However, this is a high-risk therapy with many complications. Marijn Gillissen studies the role of B cells in GvL immune responses, with the aim of increasing our understanding of these immune responses and developing less harmful, more effective therapies.
M.A. Gillissen: Allogeneic Hematopoietic Stem Cell Transplantation as Immunotherapy: B Lymphocytes versus Leukemia.
Prof. H. Spits
Dr M.D. Hazenberg
Oudezijds Voorburgwal 229 - 231 | 1012 EZ AmsterdamGo to detailpage
+31 (0)20 525 2362
This event is open to the public.